Last reviewed · How we verify
NCT05537012
Incidence of Unresectable Cases of Cervical Cancer
trial testing clinical and radiological staging, pathological types, grading and lymphovascular space invasion in Cervical Cancer in 70 participants. Completed in 31 August 2022.
31 July 2022
Quick facts
| Lead sponsor | HOSSAM ALSUKARI |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 1 March 2019 |
| Primary completion | 31 July 2022 |
| Estimated completion | 31 August 2022 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- clinical and radiological staging, pathological types, grading and lymphovascular space invasion
Conditions studied
- Cervical Cancer — all drugs for Cervical Cancer →
Sponsor
HOSSAM ALSUKARI
Who can join
Eligibility, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective : to calculate the incidence of unresectable cases of cervical cancer in gyne-oncology unit of Alexandria university hospital and to indentify its relation to pathological types, grading and lymph vascular space invasion. Patients and methods: 70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05537012
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05537012 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HOSSAM ALSUKARI
- Last refreshed: 13 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05537012.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing